Skip to content

Modulation of amygdala reactivity following rapidly acting interventions for major depression.

Joana R A Loureiro, Amber Leaver, Megha Vasavada, Ashish K Sahib, Antoni Kubicki, Shantanu Joshi, Roger P Woods, Benjamin Wade, Eliza Congdon, Randall Espinoza, Katherine L Narr

Human brain mapping May 1, 2020 DOI: 10.1002/hbm.24895 via PubMed

Summary

AI-generated from the abstract

Both electroconvulsive therapy (ECT) and ketamine reduce amygdala reactivity to positive and negative emotional faces in people with treatment-resistant depression. In a naturalistic study of 44 patients (17 receiving ECT, 27 receiving ketamine), fMRI showed decreased amygdala response after both treatments. Subtle differences between treatments appeared in the dorsolateral prefrontal cortex and insula. Changes in brain activity in the inferior parietal cortex correlated with overall symptom improvement, while frontal region changes correlated with anxiety for negative faces and anhedonia for positive faces. The findings suggest common and distinct neural mechanisms underlying fast-acting antidepressant effects on emotion processing.

Study at a glance

Characteristics Naturalistic study Peer reviewed
Sample size 44
Population Patients with major depressive disorder unresponsive to standard treatments
Interventions Electroconvulsive therapy Ketamine
Dose 0.5 mg/kg
Topics Depression Ketamine
Keywords Ect Amygdala Emotion processing
Citations 65
Key finding Both ECT and ketamine reduce amygdala reactivity to emotional faces, with treatment-specific changes in the dorsolateral prefrontal cortex and insula, and correlations between brain activity changes and symptom improvement in anxiety and anhedonia.

Abstract

Electroconvulsive therapy (ECT) and ketamine treatment both induce rapidly acting antidepressant effects in patients with major depressive disorder unresponsive to standard treatments, yet their specific impact on emotion processing is unknown. Here, we examined the neural underpinnings of emotion processing within and across patients (N = 44) receiving either ECT (N = 17, mean age: 36.8, 11.0 SD) or repeated subanesthetic (0.5 mg/kg) intravenous ketamine therapy (N = 27, mean age: 37.3, 10.8 SD) using a naturalistic study design. MRI and clinical data were collected before (TP1) and after treatment (TP2); healthy controls (N = 31, mean age: 34.5, 13.5 SD) completed one MRI session (TP1). An fMRI face-matching task probed negative- and positive-valence systems. Whole-brain analysis, comparing neurofunctional changes within and across treatment groups, targeted brain regions involved in emotional facial processing, and included regions-of-interest analysis of amygdala responsivity. Main findings revealed a decrease in amygdalar reactivity after both ECT and ketamine for positive and negative emotional face processing (p < .05 family wise-error (FWE) corrected). Subthreshold changes were observed between treatments within the dorsolateral prefrontal cortex and insula (p < .005, uncorrected). BOLD change for positive faces in the inferior parietal cortex significantly correlated with overall symptom improvement, and BOLD change in frontal regions correlated with anxiety for negative faces, and anhedonia for positive faces (p < .05 FWE corrected). Both serial ketamine and ECT treatment modulate amygdala response, while more subtle treatment-specific changes occur in the larger functional network. Findings point to both common and differential mechanistic upstream systems-level effects relating to fast-acting antidepressant response, and symptoms of anxiety and anhedonia, for the processing of emotionally valenced stimuli.

Explore topics

Comments

No comments yet.

Log in to comment